167 related articles for article (PubMed ID: 30767401)
1. An optical study of drug resistance detection in endometrial cancer cells by dynamic and quantitative phase imaging.
Yao T; Cao R; Xiao W; Pan F; Li X
J Biophotonics; 2019 Jul; 12(7):e201800443. PubMed ID: 30767401
[TBL] [Abstract][Full Text] [Related]
2. The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition.
Fukuda T; Oda K; Wada-Hiraike O; Sone K; Inaba K; Ikeda Y; Miyasaka A; Kashiyama T; Tanikawa M; Arimoto T; Kuramoto H; Yano T; Kawana K; Osuga Y; Fujii T
Gynecol Oncol; 2015 Jun; 137(3):538-45. PubMed ID: 25842161
[TBL] [Abstract][Full Text] [Related]
3. Emodin Enhances the Chemosensitivity of Endometrial Cancer by Inhibiting ROS-Mediated Cisplatin-resistance.
Ding N; Zhang H; Su S; Ding Y; Yu X; Tang Y; Wang Q; Liu P
Anticancer Agents Med Chem; 2018; 18(7):1054-1063. PubMed ID: 29256357
[TBL] [Abstract][Full Text] [Related]
4. Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure.
Sagawa Y; Fujitoh A; Nishi H; Ito H; Yudate T; Isaka K
Tumour Biol; 2011 Apr; 32(2):399-408. PubMed ID: 21113744
[TBL] [Abstract][Full Text] [Related]
5. Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines.
Smith JA; Gaikwad A; Ramondetta LM; Wolf JK; Brown J
Gynecol Oncol; 2006 Nov; 103(2):518-22. PubMed ID: 16690105
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of GLIF combination chemotherapy for taxane/platinum-refractory/resistant endometrial cancer (GOGO-EM2).
Tanaka Y; Ueda Y; Nakagawa S; Matsuzaki S; Kobayashi E; Shiki Y; Nishio Y; Takemura M; Yamamoto T; Sawada K; Tomimatsu T; Yoshino K; Kimura T
Cancer Chemother Pharmacol; 2018 Oct; 82(4):585-592. PubMed ID: 30030584
[TBL] [Abstract][Full Text] [Related]
7. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
[TBL] [Abstract][Full Text] [Related]
8. [Establishment of cisplatin-resistant human endometrial cancer cell line and the study of its resistant mechanisms].
Xu QY; Chen YH; Zhao LJ; Li XP; Wang JL; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2011 Jul; 46(7):533-7. PubMed ID: 22041447
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer.
Kanasugi M; Aoki D; Suzuki N; Susumu N; Nakata S; Horiuchi M; Udagawa Y; Nozawa S
Int J Gynecol Cancer; 2006; 16(1):409-15. PubMed ID: 16445667
[TBL] [Abstract][Full Text] [Related]
10. [SENP1 induced protein deSUMO modification increased the chemotherapy sensitivity of endometrial cancer side population cells].
Yuan ML; Bai J; Li CY; Xue N; Chen XH; Sheng F; Liu XZ; Li P
Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1362-1368. PubMed ID: 36575788
[No Abstract] [Full Text] [Related]
11. Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines.
Gentilin E; Minoia M; Bondanelli M; Tagliati F; Degli Uberti EC; Zatelli MC
Endocrine; 2017 Jun; 56(3):621-632. PubMed ID: 27585662
[TBL] [Abstract][Full Text] [Related]
12. Placental leucine aminopeptidase (P-LAP) expression is associated with chemosensitivity in human endometrial carcinoma.
Shibata K; Kikkawa F; Kondo C; Mizokami Y; Kajiyama H; Ino K; Nomura S; Mizutani S
Gynecol Oncol; 2004 Nov; 95(2):307-13. PubMed ID: 15491750
[TBL] [Abstract][Full Text] [Related]
13. Involvement of Akt isoforms in chemoresistance of endometrial carcinoma cells.
Girouard J; Lafleur MJ; Parent S; Leblanc V; Asselin E
Gynecol Oncol; 2013 Feb; 128(2):335-43. PubMed ID: 23174537
[TBL] [Abstract][Full Text] [Related]
14. Steroid and xenobiotic receptor (SXR) is a key system for the acquisition of cisplatin resistance in endometrial cancer cells.
Takami N; Sakamoto H; Yamamoto T
J Int Med Res; 2003; 31(2):59-68. PubMed ID: 12760308
[TBL] [Abstract][Full Text] [Related]
15. The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer.
Chitcholtan K; Sykes PH; Evans JJ
J Transl Med; 2012 Mar; 10():38. PubMed ID: 22394685
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of HOXA11 enhances endometrial cancer malignancy and cisplatin resistance via activating PTEN/AKT signaling pathway.
Kong C; Zhu Z; Li Y; Xue P; Chen L
Clin Transl Oncol; 2021 Jul; 23(7):1334-1341. PubMed ID: 33515421
[TBL] [Abstract][Full Text] [Related]
17. Effect of microRNA-29b on proliferation, migration, and invasion of endometrial cancer cells.
Kong J; He X; Wang Y; Li J
J Int Med Res; 2019 Aug; 47(8):3803-3817. PubMed ID: 31187677
[TBL] [Abstract][Full Text] [Related]
18. MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.
Li Y; Zhang S; Wang Y; Peng J; Fang F; Yang X
BMC Cancer; 2018 Dec; 18(1):1294. PubMed ID: 30594176
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PFKFB3 induces cell death and synergistically enhances chemosensitivity in endometrial cancer.
Xiao Y; Jin L; Deng C; Guan Y; Kalogera E; Ray U; Thirusangu P; Staub J; Sarkar Bhattacharya S; Xu H; Fang X; Shridhar V
Oncogene; 2021 Feb; 40(8):1409-1424. PubMed ID: 33420377
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study.
Sayal K; Gounaris I; Basu B; Freeman S; Moyle P; Hosking K; Iddawela M; Jimenez-Linan M; Abraham J; Brenton J; Hatcher H; Earl H; Parkinson C
Int J Gynecol Cancer; 2015 Jul; 25(6):977-84. PubMed ID: 25962114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
